Centre for Research Excellence in Cervical Cancer Control (C4)

宫颈癌控制卓越研究中心 (C4)

• 批准号: nhmrc : 1135172
• 负责人: A/Pr Andrew Vallely
• 金额: $ 168.07万
• 依托单位: NSW Cancer Council
• 依托单位国家: 澳大利亚
• 项目类别: Centres of Research Excellence
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/centre-research-excellence-control-c4/1318222
• 关键词: Centre; Research; Excellence; Cervical; Cancer

Cervical cancer remains common globally despite over 50 years of Pap testing. Australia led the world in HPV vaccination and in 2017 will be the first to deliver a national screening program based on HPV testing. Our CRE, led by cervical cancer prevention experts at CCNSW,VCS, and Kirby, will marry cross-disciplinary research and evaluation of HPV vaccination and screening to provide solid evidence about these new approaches with a view to ultimately reducing the global burden of this cancer.

尽管进行了50多年的巴氏检测，宫颈癌在全球范围内仍然很常见。澳大利亚在HPV疫苗接种方面处于世界领先地位，并将于2017年率先推出基于HPV检测的全国筛查计划。我们的CRE由CCNSW、VCS和Kirby的宫颈癌预防专家领导，将结合对HPV疫苗接种和筛查的跨学科研究和评估，为这些新方法提供坚实的证据，以期最终减轻这种癌症的全球负担。